Residency · Residency · Chronic Pain Management

Post-Surgical Chronic Pain (Persistent Postsurgical Pain)

Introduction

Persistent postsurgical pain (PPSP) is defined by the International Association for the Study of Pain as pain that develops or increases in intensity after a surgical procedure, persists beyond the expected healing period (at least 3 months after surgery), is localized to the surgical field or referred territory, and is not explained by other causes such as infection, disease recurrence, or a pre-existing pain condition. PPSP is a major but often underappreciated clinical problem, affecting 10-50% of patients after common surgical procedures and progressing to severe, disabling chronic pain in 2-10%.

Epidemiology by Surgical Procedure

The incidence of PPSP varies substantially by procedure. Thoracotomy carries the highest incidence at 25-60%, with intercostal nerve injury as the primary mechanism. Mastectomy leads to PPSP in 20-50% of patients, driven by intercostobrachial nerve injury and phantom breast pain. Inguinal hernia repair results in PPSP in 10-30% of cases, typically from injury to the ilioinguinal, iliohypogastric, or genital branch of the genitofemoral nerve. Total knee arthroplasty produces chronic pain in 10-34% of patients through infrapatellar branch of saphenous nerve injury and central sensitization. Cesarean section leads to PPSP in 6-18%. Coronary artery bypass grafting has a surprisingly high incidence of 30-50%, involving both sternotomy pain and saphenous nerve harvest site pain. Amputation produces phantom limb pain in 50-80% (discussed separately). Spine surgery results in PPSP in 10-40%, often termed failed back surgery syndrome.

Risk Factors

Preoperative Risk Factors

Pre-existing pain is the single strongest predictor of PPSP — patients with chronic pain at the surgical site or at other locations are at significantly increased risk. Pain catastrophizing, measured by the Pain Catastrophizing Scale, amplifies negative cognitive and emotional responses to pain; scores above 30 predict PPSP. Anxiety and depression independently predict PPSP, and preoperative screening with validated instruments such as the GAD-7 and PHQ-9 is recommended. Female sex confers higher PPSP risk in most surgical populations. Paradoxically, younger patients also have higher risk, possibly because of greater neural plasticity and sensitization capacity. Genetic factors, including polymorphisms in the COMT, GCH1, and OPRM1 genes, influence pain sensitivity and PPSP risk. Chronic preoperative opioid therapy increases PPSP risk through opioid-induced hyperalgesia.

Intraoperative Risk Factors

Nerve injury is the most important surgical risk factor and can occur through direct transection, compression, stretch, or thermal mechanisms. More invasive surgical approaches with greater tissue disruption increase risk (open versus laparoscopic, posterolateral thoracotomy versus VATS). Longer procedures correlate with higher PPSP incidence. Specific surgical technique choices matter — the type of mesh used in hernia repair, how the intercostobrachial nerve is handled in mastectomy, and the method of rib retraction in thoracotomy all influence outcomes.

Postoperative Risk Factors

Severe acute postoperative pain in the first 24-72 hours is the most modifiable risk factor and strongly predicts PPSP development. Patients whose pain intensity fails to follow the expected downward trajectory are at highest risk. Complications such as wound infection, hematoma, or reoperation increase PPSP risk. Prolonged postoperative opioid use beyond 90 days significantly increases the probability of chronic pain.

<image>Risk factor diagram for persistent postsurgical pain organized as a timeline showing preoperative factors (pre-existing pain, catastrophizing, anxiety/depression, opioid use, genetic predisposition) on the left, intraoperative factors (nerve injury, surgical approach, duration) in the center, and postoperative factors (acute pain severity, pain trajectory, complications, prolonged opioid use) on the right. Arrows converge on a central mechanism box showing peripheral sensitization, central sensitization, and neuroplastic changes leading to PPSP. Modifiable risk factors are highlighted in a distinct color.</image>

Pathophysiology

Transition from Acute to Chronic Postsurgical Pain

The transition from acute to chronic pain involves a cascade of changes at multiple levels. Peripheral sensitization begins as surgical tissue injury releases inflammatory mediators — prostaglandins, bradykinin, nerve growth factor, and cytokines — that sensitize nociceptors and lower their activation thresholds. When peripheral nerves are surgically damaged and fail to regenerate properly, they form neuromas with ectopic activity and upregulated sodium channels. Sustained nociceptive input from the surgical site drives central sensitization through NMDA receptor activation on dorsal horn neurons, producing wind-up (progressive increase in firing with repeated C-fiber stimulation), long-term potentiation (strengthened synaptic connections in nociceptive pathways), expansion of receptive fields (pain perceived beyond the surgical site), and loss of inhibitory control (reduced GABAergic and glycinergic inhibition). Descending facilitation from the rostral ventromedial medulla further amplifies dorsal horn excitability. Glial activation by microglia and astrocytes maintains the chronic pain state through release of pro-inflammatory mediators. Prolonged pain ultimately leads to cortical reorganization affecting the somatosensory cortex, anterior cingulate, and prefrontal cortex.

Neuropathic Component

PPSP frequently includes a neuropathic component, estimated to be present in 30-60% of cases. This is identified by characteristic descriptors — burning, shooting, electric shock-like, tingling, and numbness in a nerve distribution — and can be screened for using the DN4 questionnaire or painDETECT. Neuropathic PPSP responds to targeted therapies including gabapentinoids, TCAs, and SNRIs.

Preventive Strategies

Preoperative Prevention

Identifying high-risk patients is the first step, through screening for pre-existing pain, psychosocial risk factors (catastrophizing, anxiety, depression), and preoperative opioid use. Preoperative psychological preparation — setting realistic expectations, addressing catastrophizing, and delivering brief CBT-based interventions — may reduce PPSP risk. Pre-existing conditions such as depression, anxiety, and sleep disorders should be optimized, and preoperative opioids should be tapered when possible. The transitional pain service (TPS) model provides a dedicated multidisciplinary team of anesthesiologists, psychologists, and nurses that identifies at-risk patients, delivers preventive interventions, and follows patients across the perioperative continuum.

Multimodal Analgesia

Multimodal analgesia targets multiple pain pathways simultaneously to reduce opioid requirements and minimize central sensitization. Acetaminophen (1 g IV preoperatively, then 1 g every 6 hours) provides a ceiling analgesic effect with opioid-sparing properties. NSAIDs and COX-2 inhibitors — celecoxib 200-400 mg preoperatively, ketorolac 15-30 mg IV — deliver a significant opioid-sparing effect by reducing peripheral sensitization through their anti-inflammatory mechanism. Pregabalin (75-150 mg preoperatively, continued for 2-4 weeks) has the strongest evidence for reducing PPSP at 3-6 months, particularly after thoracotomy and cardiac surgery, and also reduces acute pain and opioid consumption. Ketamine given as a subanesthetic IV infusion (0.1-0.5 mg/kg/hour intraoperatively, continued 24-48 hours postoperatively) prevents central sensitization and long-term potentiation through NMDA receptor antagonism, with the strongest evidence in opioid-tolerant patients and high-risk surgeries. Dexamethasone (a single IV dose of 0.1-0.2 mg/kg) provides anti-inflammatory and antiemetic benefits and may contribute to PPSP prevention. IV lidocaine infusion (1-2 mg/kg/hour intraoperatively) offers sodium channel blockade and anti-inflammatory effects, with evidence for reduced PPSP after abdominal surgery.

<image>Infographic illustrating the multimodal analgesia approach for PPSP prevention, depicted as a clock-face timeline from preoperative through intraoperative to postoperative periods. Each quadrant shows specific interventions with their mechanisms: preoperative (pregabalin targeting calcium channels, celecoxib targeting COX-2), intraoperative (ketamine targeting NMDA receptors, regional anesthesia blocking afferent transmission, IV lidocaine targeting sodium channels), and postoperative (continued multimodal agents, transition to oral regimen, early mobilization). A central inset shows the dorsal horn neuron with multiple mechanism targets converging on reduced central sensitization.</image>

Regional Anesthesia

Regional anesthesia provides the most effective interruption of nociceptive transmission and is a cornerstone of PPSP prevention. Thoracic epidural analgesia is the gold standard for thoracotomy, using continuous infusion of local anesthetic with or without opioid. Paravertebral blocks are an effective alternative for thoracotomy and mastectomy, offering unilateral blockade with fewer hemodynamic effects and continuous catheter options. Transversus abdominis plane (TAP) blocks reduce acute pain and opioid consumption in abdominal and inguinal hernia surgery. Adductor canal and iPACK blocks provide saphenous nerve and posterior capsule coverage for total knee arthroplasty. Continuous peripheral nerve catheters deliver 48-72 hours of local anesthetic infusion for limb surgeries. Wound infiltration with liposomal bupivacaine provides extended-release analgesia lasting approximately 72 hours at the surgical site.

Surgical Technique Modifications

Nerve-sparing approaches — identification and preservation of the intercostobrachial nerve during mastectomy, the ilioinguinal nerve during hernia repair — reduce nerve injury. Minimally invasive surgery (VATS versus open thoracotomy, laparoscopic versus open abdominal surgery) reduces tissue trauma and nerve injury. Lightweight mesh in hernia repair produces less inflammatory response and nerve entrapment than heavyweight mesh.

Treatment of Established PPSP

Pharmacotherapy

When a neuropathic component is present, neuropathic pain agents (pregabalin, gabapentin, duloxetine, nortriptyline) should be used following standard neuropathic pain treatment guidelines. Topical agents including lidocaine 5% patches and capsaicin 8% patch are useful for localized neuropathic PPSP. An NSAID trial is appropriate for a persistent inflammatory or nociceptive component. Opioids initiated perioperatively should be tapered or discontinued, and long-term opioid therapy for PPSP should be avoided.

Interventional Treatments

Peripheral nerve blocks of the suspected injured nerve (intercostal, ilioinguinal, intercostobrachial) serve both diagnostic and therapeutic purposes. Pulsed radiofrequency offers neuromodulation of the affected peripheral nerve or DRG. Post-surgical neuromas can be treated with injection or excision. Spinal cord stimulation is an option for refractory PPSP, particularly post-thoracotomy and post-herniorrhaphy pain. Scar infiltration with local anesthetic and corticosteroid addresses scar-related pain.

Rehabilitation and Psychology

Physical therapy focusing on scar mobilization, desensitization, and functional restoration is important. Cognitive behavioral therapy addresses catastrophizing, fear-avoidance, and pain-related disability. Acceptance and commitment therapy promotes psychological flexibility and values-based activity despite persistent pain.

<image>Flowchart for the management of persistent postsurgical pain, beginning with assessment (characterize pain as neuropathic vs nociceptive vs mixed using DN4 questionnaire, identify modifiable factors, functional assessment), branching into pharmacotherapy pathway (neuropathic agents for neuropathic component, NSAIDs for inflammatory component, opioid taper), interventional pathway (diagnostic nerve blocks, pulsed radiofrequency, neuroma treatment, neuromodulation for refractory cases), and rehabilitation pathway (physical therapy, psychology, multidisciplinary pain program). Decision points for escalation between pathways are clearly marked.</image>

Clinical Pearls

Severe acute postoperative pain is the most important modifiable risk factor for PPSP, and investing resources in optimizing acute pain management during the first 48-72 hours pays dividends in preventing chronic pain. Perioperative pregabalin (75-150 mg preoperatively, continued for two weeks postoperatively) has the strongest evidence for PPSP prevention and should be considered for high-risk surgeries such as thoracotomy, mastectomy, and cardiac surgery. Ketamine infusions are particularly valuable in opioid-tolerant patients undergoing major surgery, addressing NMDA receptor-mediated central sensitization while reducing opioid requirements. The Transitional Pain Service model, pioneered at Toronto General Hospital, represents the gold standard for perioperative pain management in high-risk patients and has demonstrated reductions in both PPSP and persistent opioid use. Every case of PPSP should be assessed for a neuropathic component using validated screening tools, because neuropathic PPSP responds to targeted therapies and may benefit from early interventional treatment. Surgical nerve injury is often preventable, and pain specialists should advocate for nerve-sparing techniques and minimally invasive approaches when feasible.

References

1. Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet. 2006;367(9522):1618-1625.
2. Katz J, Seltzer Z. Transition from acute to chronic postsurgical pain: risk factors and protective factors. Expert Rev Neurother. 2009;9(5):723-744.
3. Chaparro LE, Smith SA, Moore RA, et al. Pharmacotherapy for the prevention of chronic pain after surgery in adults. Cochrane Database Syst Rev. 2013;7:CD008307.
4. Katz J, Weinrib A, Fashler SR, et al. The Toronto General Hospital Transitional Pain Service: development and implementation of a multidisciplinary program to prevent chronic postsurgical pain. J Pain Res. 2015;8:695-702.

Read this lecture as Markdown